The Companies announced the European Commission adopted the decision to grant marketing authorization of GALLIPRANT® (grapiprant tablets) in the European Union.
The Company announced its first quarter 2017 financial results. For the quarter ended March 31, 2017, Aratana reported total net revenues of $3.8 million and a net loss of $12.6 million or $0.34 diluted loss per share.
The Company announced that it has entered into a securities purchase agreement with several institutional investors in a registered direct offering.
The Company announced that it recently met with the U.S. Food and Drug Administration Center for Veterinary Medicine (CVM) regarding the proposed manufacturing transfer of ENTYCE® (capromorelin oral solution).
The Company will host a live conference call on Tuesday, May 9, 2017 at 8:30 a.m. ET to discuss financial results from the first quarter ended March 31, 2017.
The Company announced its fourth quarter and full year 2016 financial results. Aratana will host a live conference call on Tuesday, March 14, 2017 at 8:30 a.m. ET to discuss the results.
The Company plans to present at the Barclays Capital Global Healthcare Conference on Thursday, March 16, 2017 at 9:00 a.m. ET in Miami.
The Company will host a live conference call on Tuesday, March 14, 2017 at 8:30 a.m. ET to discuss financial results from the fourth quarter and full year ended December 31, 2016.
Aratana to attend North American Veterinary Conference February 5-9 and will provides update on availability of ENTYCE® (capromorelin oral solution) via webcast Monday, February 6 at 8 a.m. ET.
Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY), and Aratana Therapeutics, Inc. (NASDAQ: PETX) have announced veterinarians have a new targeted tool for the management of pain and inflammation associated with canine osteoarthritis (OA).
The Company was honored with Animal Pharm’s Best Company in North America 2016.
The Company announced its third quarter 2016 financial and operational results.
The Company plans to present at the 2016 Credit Suisse Healthcare Conference on Tuesday, November 8 at 8:30 a.m. MT in Scottsdale, Arizona and at Stifel Healthcare Conference 2016 on Wednesday, November 16 at 8:45 a.m. ET in New York City.
The Company will host a live conference call on Friday, November 4, 2016 at 8:30 a.m. ET to discuss financial results from the third quarter ended September 30, 2016.
Aratana-sponsored presentation for veterinarians at ACVS featured a newly available therapeutic option for extended pain control.
The Company announced making NOCITA® (bupivacaine liposome injectable suspension) commercially available to veterinarians in the United States. CVM approved Nocita as a local post-operative analgesia for cranial cruciate ligament surgery in dogs on August 12, 2016.
Each year, thousands of pet owners listen as their veterinarian informs them that their dog has a knee injury and may benefit from surgery. Bert Shelley, DVM, MS DACVS of Bradford Park Veterinary Hospital in Springfield, Missouri sees local referrals to perform several cranial cruciate ligament surgeries and has the goal of “mimicking” the function of the CCL.